Latin America Next Generation Sequencing Market (2020-2027)
The Latin America NGS Market is expected to grow at a CAGR of 14.3% from 2020 to 2027 to reach $714.8 million by 2027.
- Published
- Jul 2020
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 104409
- Base year
- 2019
- 2027 · FORECAST
- $714.8M
- 2027
- $714.8M
- CAGR 2020–2027
- 14.3%
2019 baseline · 2020–2027 forecast at 14.3% CAGR · hover a bar for the value
Key highlights
Based on technology, the sequencing by synthesis segment is estimated to hold the major share of the Latin America next-generation sequencing market in 2020 and is also projected to grow at the fastest CAGR during the forecast period. The large share of this segment is attributed to the high accuracy of SBS technology in DNA sequencing, highest yield of error free throughput, and growing incorporation of this technology in NGS instrumentation.
Based on application, clinical applications will register the fastest growth during the analysis period, mainly due to the growing incidence of cancer and increasing volume of diagnostic procedures and treatment rates for the disease.
Based on end-user, the clinical diagnostic laboratories segment is estimated to account for the largest share of the Latin America next-generation sequencing market in 2020. Rising pool of cancer patient population visiting diagnostic laboratories for diagnosis & treatment owing to easy accessibility is driving the growth of this end user segment. Also, the improving healthcare infrastructure across the countries in this region also supports the growth of the next-generation sequencing market for clinical diagnostic laboratories.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2019 |
| Estimated Year | 2020 |
| Forecast Period | 2020–2027 |
| Market Size (2027) | USD 714.8 million |
| CAGR (2020–2027) | 14.3% |
| Format | PDF, Excel & Cloud Portal · 200 pages |
| Segments Covered | By Type: Library Preparation & Target Enrichment, Quality Control, Other Consumables, NGS Platforms/Instruments Illumina NGS Platforms/Instruments, Thermo Fisher Scientific NGS Platforms/Instruments, Pacific Biosciences NGS Platforms/Instruments, Oxford Nanopore NGS Platforms/Instruments, Others, Software, Services · By Sequencing Type: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing · By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single-Molecule Real-Time Sequencing, Nanopore Sequencing · By Application: Clinical Application Oncology, Reproductive Health Diagnostics Non-Invasive Pre-natal Testing, Carrier Screening, In-Vitro fertilization, Newborn Screening, Research Application Drug Discovery, Agriculture & Animal Research, Others · By End User: Clinical Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others |
| Countries Covered | Latin America (Brazil, Argentina, Chile, Rest of Latin America), North America (Mexico) |
| Key Companies | Illumina, Inc., Thermo Fisher Scientific Inc., California, Inc., Qiagen N.V., Oxford Nanopore Technologies Ltd, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., PerkinElmer, Inc., F. Hoffmann-La Roche AG, Genomics, Inc. |
Report overview
Segments covered: type, sequencing type, technology, application, end user. Regions: Latin America, North America.
Next generation sequencing is a technology used to determine the sequence of DNA or RNA to study genetic variation associated with diseases. The speed, throughput, and accuracy of NGS has revolutionized genetic analysis and enabled its use in new applications in genomic and clinical research; reproductive health; and environmental, agricultural, and forensic science. The growth in this market is majorly driven by the technological advancements in sequencing procedures, surge in genome mapping programs, and increase in drug discovery platforms demanding NGS technology. Further, the growth in personalized medicine research, growing government initiatives for large-scale genomic sequencing projects, and emergence of cloud computing as a potential data management service supports the growth of the Latin America NGS market.
Throughout the COVID-19 pandemic, uncertainty in tests and false positive results led to ingenuity and raised questions on the global healthcare system including Latin America. In such times, next generation sequencing turned out to be a blessing in disguise and helped the healthcare systems to effectively diagnose the disease. According to the U.S. Food and Drug Administration (FDA), the information about the sequence of viral genome can help the researchers to identify how the virus mutates, which will be crucial for ongoing efforts to continue to learn and fight this virus.
Realizing its importance, the key players have also shifted their focus towards development of advanced instruments and products, which could aid in COVID-19 diagnosis. For instance, recently in June 2020, Illumina, Inc. (U.S.) received an emergency authorization from the FDA for its COVID-19 test designed to sequence the full genome of the novel coronavirus. COVIDSeq test is capable of processing over 3,000 samples at once from nasopharyngeal and oropharyngeal swabs and gives results in 24 hours. Also, RNA sequencing was employed in positive samples to develop epidemiological, phylodynamic models of the spread of SARS-CoV-2 in various regions including the Latin America.
Owing to the advantages offered by this technology and rapidly rising cases of COVID-19, the demand for NGS instruments and test kits is exponentially increasing in Latin America, thereby supporting the growth of the NGS market in the region.
Report infographic
Market dynamics
1 factors across 1 forceIncrease in drug discovery platforms demanding NGS technology supports the market growth
Due to NGS capabilities, increasing applications, and growing trend of personalized medicine, various projects related to drug development, research, and clinical diagnostics procedures are ongoing in the region. According to the National Center for Biotechnology Information (NCBI), as of 2017, 221 NGS platforms and 118 research groups in Latin America were involved in developing cancer genomics project. For instance:
- In Brazil, due to huge progress in the next-generation sequencing (NGS) techniques, various projects have been initiated to study HIV genetic diversity through generation of HIV complete or near full-length genomes (NFLG) and improving the characterization of intra- and interhost diversity of viral populations.
- Similarly, in Colombia, NGS is used to detect, diagnose, and control viral diseases in plants to generate plants resistant to viral infections.
- Also, in Chile, screening by Next Generation Sequencing (NGS) is used to detect porcine 3 circovirus type 3. The detection of viral species of porcine using its RNA and DNA genomes simultaneously can be useful for detection of swine viral emerging diseases worldwide.
Table of contents
13 chapters · 136 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2020) | Fastest growth (2020–2027) |
|---|---|---|
| By Sequencing Type | Targeted sequencing | — |
By Sequencing Type
- Targeted sequencing segment to dominate the NGS market through 2027
- The targeted sequencing segment is estimated to command the largest share of the next-generation sequencing technologies market in Latin America in 2020, owing to its capability to call variants, comparative cost effectiveness, and ability to generate manageable data volumes with reliable results.
Geographic analysis
Latin America
Fastest growthBrazil is estimated to command the largest share of the Latin America NGS market in 2020 and will be the fastest growing market due to growing investments in genomic research, growing research activities related to treatment of viral and infectious diseases, and high focus of key players on this country. Brazil: The fastest growing market
Competitive landscape
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- California, Inc.
- Qiagen N.V.
- Oxford Nanopore Technologies Ltd
- Bio-Rad Laboratories, Inc.
- Beckman Coulter, Inc.
- PerkinElmer, Inc.
- F. Hoffmann-La Roche AG
- Genomics, Inc.
Frequently asked questions
Cite this report
Meticulous Research. (2020). Latin America Next Generation Sequencing Market- Opportunity Analysis and Industry Forecast (2020-2027) (Report No. MRHC - 104409). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/latin-america-next-generation-sequencing-market-5106